Skandinaviska Enskilda Banken Ab (Publ) Immuno Gen, Inc. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $623,000 - $1.5 Million	50,000 Added 103.06%	98,515 $2.92 Million
Q3 2023 Nov 09, 2023	BUY	$14.09 - $19.87 $683,576 - $963,993	48,515 New	48,515 $769,000
Q3 2020 Nov 12, 2020	SELL	$3.45 - $4.89 $490,590 - $695,358	-142,200 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$3.32 - $5.34 $472,104 - $759,348	142,200 New	142,200 $653,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.